Revealing My WORST Stock Investment of 2026!
1 extracted signal · 0 resolved · 1 still active
The Patient InvestorIndependent analyst profile- Source published
- 20 Oct 2026, 18:30 UTC
- Recorded by Tahlil Plus
- 20 Oct 2026, 21:39 UTC

AI-generated source summary
The video discusses SoFi Technologies (SOFI), highlighting its significant year-to-date decline of 48% and its current trading price of $14.30. The speaker notes personal experiences of buying SOFI at $14 in February and later at $8, resulting in a cost average below the current price, and mentions that the stock is currently up 120% for them from their lowest buy-in point. However, the analysis shifts to a more fundamental view. The speaker points out that while SoFi's share count has increased significantly, its tangible book value per share has more than doubled over the last four years, suggesting dilution has been less impactful than for some other companies. The company is identified as a lender, offering personal loans and student loans with strong average borrower income and FICO scores, indicating a decent quality customer base that can withstand economic weakness. The discussion also touches on SoFi's stablecoin initiative, SoFi USD, which is backed by reserves and offers a high interest rate. Despite the stock's historical performance and some fundamental strengths, the speaker highlights concerns about SoFi's innovation lagging behind competitors like Robinhood, which has been aggressively introducing new products and services. The valuation is also mentioned as being potentially too high previously, but now trading at a lower P/E ratio. The speaker's personal stance is to trim the position, not sell it entirely, and potentially add more if the stock becomes even more undervalued, while also expressing a preference for Robinhood due to its innovation.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
